Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

CHECKVIR Optimizing Immune Checkpoint Inhibitor Payloads for Oncolytic Virus-Based Immunotherapy

Coordinator
Klinikum Der Technischen Universität München (tum Klinikum), Germany
Runs
1 March 2026 to 31 August 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101293194

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite novel innovations in immune-oncology over the last decades, up to 80% of solid cancers remain unresponsive to currently available approaches, highlighting an urgent unmet clinical need. CHECKVIR aims to develop and validate a next-generation oncolytic virus-based immunotherapy approach to overcome treatment resistance in solid cancers. The technology leverages an optimized oncolytic virus platform that is engineered to elicit immune checkpoint inhibitory functions, thereby combining efficient tumor cell killing and a potent immunotherapy approach within a single drug.

Building upon innovative viral vector engineering and immune-modulating strategies developed within the ERC Starting Grant action, ONCO-VAX, CHECKVIR will enable critical proof of concept activities, leading to identification of a clinical development candidate and a de-risked path towards commercialization in order to enable real-world impact. By combining ground-breaking translational research with a preclinical validation, CHECKVIR will deliver an innovative and readily translatable solution to address the ongoing challenges in immune oncology and provide hope for improved outcomes for cancer patients worldwide who urgently need effective solutions.

Topics

Who is involved

OrganisationCityCountryRole
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI